(1R)-1-(N,N-diethylcarbamoyl)ethyl methyl (2E)but-2-ene-1,4-dioate | 1208230-45-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (1R)-1-(N,N-diethylcarbamoyl)ethyl methyl (2E)but-2-ene-1,4-dioate
• 英文别名: 4-O-[(2R)-1-(diethylamino)-1-oxopropan-2-yl] 1-O-methyl (E)-but-2-enedioate
• CAS: 1208230-45-8
• 化学式: C₁₂H₁₉NO₅
• 分子量: 257.287
• InChiKey: BSSVVSMEAYBMMA-FCZSHJHJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Methods of treating multiple sclerosis
  申请人：Biogen MA Inc.

  公开号：US11007166B2

  公开（公告）日：2021-05-18

  Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.

  本文提供了用富马酸盐治疗多发性硬化症的方法，其中富马酸盐是富马酸二烷基酯、富马酸单烷基酯、富马酸二烷基酯和富马酸单烷基酯的组合、富马酸单烷基酯的原药、前述任一物质的氚化形式、或前述任一物质的药学上可接受的盐、凝胶体、溶胶体、同系物或立体异构体、或前述任一物质的组合。本文提供的方法通过告知和监测接受治疗的患者进行性多灶性白质脑病的情况，和/或通过监测淋巴细胞计数，提高了治疗的安全性。
• Methods of Treating Multiple Sclerosis
  申请人：Biogen MA Inc.

  公开号：US20170354630A1

  公开（公告）日：2017-12-14

  Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
• METHODS OF TREATING MULTIPLE SCLEROSIS
  申请人：Biogen MA Inc.

  公开号：US20200345679A1

  公开（公告）日：2020-11-05

  Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
• [EN] METHODS OF TREATING MULTIPLE SCLEROSIS<br/>[FR] MÉTHODES DE TRAITEMENT DE LA SCLÉROSE EN PLAQUES
  申请人：BIOGEN MA INC

  公开号：WO2016081355A1

  公开（公告）日：2016-05-26

  Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
• [EN] METHODS AND COMPOSITIONS FOR THE INTRAVENOUS ADMINISTRATION OF FUMARATES FOR THE TREATMENT OF NEUROLOGICAL DISEASES<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR L'ADMINISTRATION INTRAVEINEUSE DE FUMARATES POUR LE TRAITEMENT DE MALADIES NEUROLOGIQUES
  申请人：BIOGEN MA INC

  公开号：WO2016153957A2

  公开（公告）日：2016-09-29

  Disclosed herein are methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases, such as stroke, amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, Parkinson's disease, and Multiple Sclerosis.